Effect of XELOX regimens plus combination of endostar and thalidamide as first?line treatment for advanced colorectal cancer
10.3760/cma.j.issn.1008?6315.2019.05.012
- VernacularTitle:恩度和沙利度胺联合XELOX一线治疗晚期结直肠癌的效果观察
- Author:
Yuzhi LI
1
;
Yangyi BAO
;
Feng SUN
;
Ting ZHU
Author Information
1. 安徽医科大学第三附属医院 安徽省合肥市第一人民医院血液肿瘤科 230061
- Keywords:
Recombinant human endostatin;
Endostar;
Thalidomide;
Advanced colorectal cancer
- From:Clinical Medicine of China
2019;35(5):436-440
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of two antiangiogenic drugs (recombinant human endostatin endostar and thalidomide ) combined with capecitabine and oxaliplatin (XELOX) regimens in the treatment of advanced colorectal cancer.Methods From January 2015 to May 2018,40 patients of advanced metastatic colorectal cancer with organ metastasis and non?resectable were selected from the first people′s hospital of Hefei and Anhui Provincial Hospital, and they were randomly divided into treatment and control group, with 20 cases in each group.The treatment group received intravenous infusion (IV) of endostar for continuous 7 days (day 1～7) combined with oral administration of thalidomide for continuous 14 days (day 1～14) plus XELOX regimens after the fifth dose of endostar (day 6～19),and the control group was treated with XELOX regimen (day6～19).Results The objective response rate (ORR) was 50%(10／20) and 20%(4／20) respectively (χ2＝3.956,P＜0.05),the disease control rate (DCR) was 85%( 17／20) and 70%(14／20) respectively ( χ2＝1.290,P＞0.05),and the median progression free survival (mPFS) was 6.8 in both groups.There was no significant difference in Karnofsky performance score ( KPS) and incidence of adverse reactions between the two groups before and after treatment (P＞0.05).Conclusion Combination of endostar and thalidamide plus XELOX regimen as first?line treatment have better antitumor activity and are well?tolerated in patients with advanced colorectal cancer.
